HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025

NCT ID: NCT02095210

Last Updated: 2020-10-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2014-08-13

Brief Summary

This is an open-labeled, exploratory, single center study. Patients with a big primary breast cancer (≥ 3 cm) or metastatic first line, routinely have their HER2-expression determined by biopsy. Patients having a HER2-positive tumor will be recruited to the study. A [18F]FDG PET/ceCT scan is performed for the measurement of uptake in the tumour and diagnosis of possible metastases. Each subject will receive a single injection of the investigational product [68Ga]ABY-025, followed by measurement of uptake in the tumour or metastases and in normal organs. The investigations will be repeated after HER2 directed therapy.

Detailed Description

see above

Conditions

HER2-positive Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

[68Ga]ABY-025 PET imaging

Radiolabeled \[68Ga\]ABY-025

Group Type: EXPERIMENTAL

Radiolabeled [68Ga]ABY-025

Intervention Type: OTHER

Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.

Interventions

Radiolabeled [68Ga]ABY-025

Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.

Intervention Type: OTHER

Other Intervention Names

tracer for HER2

Eligibility Criteria

Inclusion Criteria

1. Subject is > 18 years of age

2. Histologically or cytologically confirmed diagnosis of breast adenocarcinoma ≥ 3 cm determined by ultrasound, or locally advanced breast cancer (LABC: T3-4NxMx or TxN2-3Mx)

3. HER2-positiv breast cancer first recurrence

4. HER2-positiv breast cancer primary metastatic

5. HER2 status has been determined on biopsy material from the primary tumour and found to be HER2-positive, defined as a DAKO HercepTest™ score of 3+ or else 2+ and FISH positive

6. [18F]FDG PET/ceCT performed within 7 days before administration of IMP

7. ECOG performance status of =< 2

8. Hematological, liver and renal function test results within the following limits:

• White blood cell count: > 2.0 x 10^9/L
• Haemoglobin: > 5.0 mmol/L
• Platelets: > 50.0 x 10^9/L
• ALT, ALP: =< 3 times Upper Limit of Normal
• Bilirubin =< 2.0 times Upper Limit of Normal
• Serum creatinine: Within Normal Limits

9. A negative pregnancy test (serum beta-HCG) at screening for all subjects of childbearing potential

10. Subject is capable to undergo the diagnostic investigations to be performed in the study

11. Informed consent

Exclusion Criteria

• 1. Known hypersensitivity to Dotarem® 2. Active known autoimmune disease or history of autoimmune disease 3. Active serious infection according to investigator evaluation 4. Known HIV positive or chronically active hepatitis B or C 5. Administration of other investigational medicinal product within 30 days of screening 6. Pregnant or breast-feeding 7. Women capable of childbearing not using a sufficient non-hormonal method of birth control 8. Other primary malignancies (including primary brain tumors) within the last 5 years before inclusion, with exception of sufficiently treated in situ carcinoma of the cervix, squamous carcinoma of the skin or sufficiently controlled limited basal cell carcinoma of the skin 9. Signs of any other disease, metabolic or psychological dysfunction, findings at physical examination or laboratory findings, which give reasonable suspicion of a disease or condition that would contraindicate use of the IMP, could influence the patient's compliance with the study routines or involves an increased risk for treatment-related complications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dorte Nielsen

OTHER

Sponsor Role: lead

Responsible Party

Dorte Nielsen

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Malgorzata K Tuxen, MD, P.hd.

Role: PRINCIPAL_INVESTIGATOR

Consultant

Locations

Herlev University Hospital, Oncology Department

Herlev, , Denmark

Countries

Denmark

Other Identifiers

MA1021

Identifier Type: -

Identifier Source: org_study_id